Is neurodegeneration a systemic metabolic condition?
London biotech Vesalic reports a disease-specific alteration in extracellular vesicle (EV) lipid composition in the blood of ALS patients and claims these EVs carry a toxic cargo that can harm motor neurons. The company is developing a blood-based biomarker platform it says detects ALS with >90% accuracy, alongside a therapeutic program to neutralize EV cargo, and is seeking partners to use the biomarkers in clinical trials to test upstream metabolic hypotheses for neurodegeneration.
Why it mattersEV lipid signature in blood (>90% accuracy) supports upstream metabolic targets; prioritize trials validating Vesalic's markers.
Entities Mentioned
Vesalic
People Mentioned
Danny Sullivan